Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Lexicon Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FDA END-OF-PHASE 2 MEETING FOR PILAVAPADIN IN DPNP TO BE HELD BY YEAR-END ALL IND-ENABLING STUDIES OF LX9851 FOR OBESITY COMPLETED AND SUBMITTED TO LICENSEE NOVO NORDISK SITE INITIATION FOR SONATA-HCM PHASE 3 STUDY OF SOTAGLIFLOZIN IN BOTH OBSTRUCTIVE AND NON-OBSTRUCTIVE HCM COMPLETED; ENROLLMENT COMPLETION ON TARGET FOR 2026 ADDITIONAL DATA IN SUPPORT OF POTENTIAL RESUBMISSION OF ZYNQUISTA FOR TYPE 1 DIABETES SUBMITTED TO FDA CONFERENCE CALL AND WEBCAST AT 8:30 AM ET  THE WOODLANDS, TEXAS, NOV. 06, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX), TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025, AND PROVIDED AN UPDATE ON KEY CORPORATE MILESTONES AND ACCOMPLISHMENTS. LEXICON USHERED IN 2025 WITH AN AMBITIOUS SLATE OF OBJECTIVES EMBRACING AND DRIVING OUR RENEWED R&D FOCUS, SAID MIKE EXTON, PH.D.

LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES R&D UPDATES

THE WOODLANDS, TEXAS, NOV. 04, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC.  (NASDAQ: LXRX) TODAY ANNOUNCED THAT DATA FROM THREE STUDIES OF SOTAGLIFLOZIN WILL BE PRESENTED DURING UPCOMING MEDICAL MEETINGS. TWO STUDIES WILL BE PRESENTED AT THE AMERICAN HEART ASSOCIATION'S (AHA) SCIENTIFIC SESSIONS 2025, BEING HELD NOVEMBER 7-10 AT THE ERNEST N.

DATA DEMONSTRATING UNIQUE BENEFITS OF SOTAGLIFLOZIN IN DIVERSE PATIENT POPULATIONS WILL BE PRESENTED AT THE HYPERTROPHIC CARDIOMYOPATHY SOCIETY AND AMERICAN HEART ASSOCIATION'S SESSIONS 2025 IN NEW ORLEANS

THE WOODLANDS, TEXAS, OCT. 30, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THE COMPANY WILL RELEASE ITS THIRD QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, NOVEMBER 6, 2025, PRIOR TO MARKET OPEN. MANAGEMENT WILL CONDUCT A CONFERENCE CALL AND LIVE WEBCAST AT 8:30 A.M. ET (7:30 A.M. CT) THAT DAY TO DISCUSS THE FINANCIAL RESULTS AND TO PROVIDE A BUSINESS UPDATE.

LEXICON PHARMACEUTICALS TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 6, 2025

 RESULTS SUPPORT ADVANCEMENT OF 10 MG DOSE INTO PHASE 3 DEVELOPMENT   END-OF-PHASE 2 MEETING REQUEST ACCEPTED BY U.S. FDA; PARTNERSHIP DISCUSSIONS PROGRESSING  THE WOODLANDS, TEXAS, OCT. 14, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THE COMPANY PRESENTED ADDITIONAL CLINICAL DATA AND PROGRAM UPDATES FROM ITS PHASE 2 PILAVAPADIN PROGRAM AT THE 19TH ANNUAL PAIN THERAPEUTICS SUMMIT. THESE DATA FOLLOW THE TOPLINE RESULTSFROM THE PHASE 2B PROGRESS STUDY OF PILAVAPADIN IN DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP) ANNOUNCED IN MARCH OF 2025, WHICH IDENTIFIED 10 MG ONCE DAILY AS THE MOST CLINICALLY MEANINGFUL AND APPROPRIATE DOSE TO ADVANCE INTO PHASE 3 DEVELOPMENT.

LEXICON PHARMACEUTICALS PRESENTS ADDITIONAL PILAVAPADIN DATA IN DIABETIC PERIPHERAL NEUROPATHIC PAIN AT 19TH ANNUAL PAIN THERAPEUTICS SUMMIT

DIVERSE GROUP OF STAKEHOLDERS ALIGNED AROUND THE IMPORTANCE OF ELEVATING PUBLIC AWARENESS OF NEED FOR NEW TREATMENTS FOR CHRONIC PAIN AND THE NEED TO EXPAND THE ALTERNATIVES TO PAIN ACT DIVERSE GROUP OF STAKEHOLDERS ALIGNED AROUND THE IMPORTANCE OF ELEVATING PUBLIC AWARENESS OF NEED FOR NEW TREATMENTS FOR CHRONIC PAIN AND THE NEED TO EXPAND THE ALTERNATIVES TO PAIN ACT

LEXICON PHARMACEUTICALS CONVENES ROUNDTABLE TO ADDRESS PUBLIC POLICY GAPS FOR PEOPLE WITH CHRONIC PAIN

DATA OBTAINED FROM ONGOING THIRD-PARTY FUNDED, INVESTIGATOR-SPONSORED TRIALS HAVE BEEN SUBMITTED IN EFFORT TO ADDRESS THE DECEMBER 2024 COMPLETE RESPONSE LETTER

LEXICON PHARMACEUTICALS ANNOUNCES UPDATE ON SUBMISSION OF ADDITIONAL DATA TO U.S. FDA SUPPORTING THE BENEFIT-RISK PROFILE OF ZYNQUISTA IN TYPE 1 DIABETES

PILAVAPADIN 10 MG RESULTED IN A TWO-POINT REDUCTION FROM BASELINE IN AVERAGE DAILY PAIN SCORES (ADPS) BY WEEK 11 AND WAS WELL TOLERATED IN PROGRESS PHASE 2B STUDY PILAVAPADIN 10 MG RESULTED IN A TWO-POINT REDUCTION FROM BASELINE IN AVERAGE DAILY PAIN SCORES (ADPS) BY WEEK 11 AND WAS WELL TOLERATED IN PROGRESS PHASE 2B STUDY

PILAVAPADIN PROVIDES MEANINGFUL PAIN REDUCTION IN ADULTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP) IN DATA PRESENTED AT THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD) AND NEURODIAB ANNUAL MEETINGS

PRESENTATIONS COLLECTIVELY HIGHLIGHT PILAVAPADIN'S POTENTIAL TO IMPROVE PAIN MANAGEMENT CARE FOR PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP)

LEXICON PHARMACEUTICALS TO PRESENT ADDITIONAL CLINICAL DATA ON PILAVAPADIN AT THREE UPCOMING MEDICAL MEETINGS

LEXICON PHARMACEUTICALS ANNOUNCES SUBMISSION OF ADDITIONAL DATA TO U.S. FDA SUPPORTING THE BENEFIT-RISK PROFILE OF ZYNQUISTA IN TYPE 1 DIABETES

THE WOODLANDS, TEXAS, SEPT. 04, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT NEW DATA DEMONSTRATING THE REDUCTION OF NEUROPATHIC PAIN BY PILAVAPADIN IN PRECLINICAL MODELS OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN) AND MULTIPLE SCLEROSIS (MS) AT THE 9TH INTERNATIONAL CONGRESS ON NEUROPATHIC PAIN - (NEUPSIG) 2025.

LEXICON PHARMACEUTICALS TO PRESENT NEW PRECLINICAL DATA ON PILAVAPADIN IN CHEMOTHERAPY-INDUCED PAIN AND MULTIPLE SCLEROSIS PAIN AT NEUPSIG 2025

THE WOODLANDS, TEXAS, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED DATA FROM A STUDY OF PATIENTS DESCRIBING THE PHYSICAL AND PSYCHOLOGICAL IMPACT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP), DESPITE TREATMENT WITH AVAILABLE OVER-THE-COUNTER AND PRESCRIPTION PAIN RELIEVERS WILL BE PRESENTED AT PAINWEEK 2025. THE CONFERENCE IS BEING HELD SEPTEMBER 2-4, 2025, AT THE COSMOPOLITAN IN LAS VEGAS, NEVADA.

LEXICON PHARMACEUTICALS ANNOUNCES PRESENTATION OF DIABETIC PERIPHERAL NEUROPATHIC PAIN PATIENT INSIGHTS AT PAINWEEK 2025

THE WOODLANDS, TEXAS, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC.(NASDAQ: LXRX) ANNOUNCED THAT A POST-HOC ANALYSIS (EFFICACY OF SOTAGLIFLOZIN AMONG OLDER ADULTS: A POOLED ANALYSIS OF SCORED AND SOLOIST-WHF) OF CLINICAL DATA WAS PRESENTED SUNDAY, AUGUST 31, DURING AN ORAL PRESENTATION AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) 2025 CONGRESS IN MADRID, SPAIN.

SOTAGLIFLOZIN PROVIDES CONSISTENT RELATIVE RISK REDUCTION IN HEART FAILURE AND MAJOR CARDIOVASCULAR EVENTS ACROSS ALL AGE RANGES, INCLUDING GREATER THAN 75, IN DATA PRESENTED AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) 2025 CONGRESS

Lexicon Pharmaceuticals, Inc.

LXRX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Lexicon Pharmaceuticals, Inc.

LXRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LXRX